mRNA Vaccine and Therapeutics Market (3rd Edition): Industry Trends and Global Forecasts, till 2035
The mRNA Vaccine and Therapeutics Market is valued at USD 9 billion in 2024 growing at a CAGR of 16% during the forecast period 2026-2035.
Messenger ribonucleic acid (mRNA) is a form of single-stranded ribonucleic acid (RNA) that plays a crucial role in transferring genetic information necessary for protein synthesis. The instructions encoded in mRNA for producing proteins are relayed from a DNA strand to ribosomes, where they are translated into functional proteins. The advent of mRNA therapeutics and vaccines has emerged as a groundbreaking alternative to traditional treatment methods. Following the COVID-19 pandemic, mRNA therapeutics and vaccines have gained substantial attention, establishing themselves as a revolutionary class of drugs for treating not only COVID-19 but also various other conditions, including infectious diseases, cancer, genetic disorders, and more.
To date, four mRNA-based vaccines have received approval for COVID-19 treatment, with numerous additional candidates currently undergoing evaluation as potential therapies. The overall success of mRNA-based vaccines and therapies against COVID-19 has piqued the interest of many investors, particularly in small and emerging biotechnology companies focused on mRNA technology.
The achievements in mRNA therapeutics and vaccines have spurred increased research activity in the next-generation RNA therapeutics market. A robust pipeline of mRNA-based therapeutics and vaccines is also propelling growth in the mRNA synthesis and manufacturing sector, as drug developers seek contract services to scale up the production of mRNA-based treatments.
Key Market Segments
Application Area
- Covid-19
- Other Indications
- Influenza
- Respiratory Syncytial Virus Infection
- Cytomegalovirus Diseases
- North America
- Europe
- Asia-Pacific
- Latin America
- Rest of the World
- A general introduction to mRNA, featuring insights on the historical evolution of mRNA therapeutics and vaccines. It also presents elaborate description on advantages associated with mRNA therapeutics and vaccines. It also features some of the key applications of both mRNA therapeutics and mRNA vaccines. Additionally, the chapter includes details on the various types of delivery routes and delivery strategies for mRNA drugs. Further, the chapter discusses the challenges associated with large scale adoption of mRNA therapeutics and vaccines and the associated future perspectives.
- A detailed overview of the overall market landscape of mRNA therapeutics and vaccines, based on several relevant parameters, such as phase of development (marketed, phase III, phase II, phase I, preclinical and discovery), type of drug candidate (mRNA vaccine and mRNA therapeutic), therapeutic area (infectious diseases, oncological disorders, genetic disorders, neurological disorders, autoimmune disorders, pulmonary disorders and other therapeutic area), type of delivery system (lipid nanoparticles, lipopolyplex, liposomes, direct transfer, self-amplifying RNA platform and other delivery system), type of molecule encoded (spike protein, glycoprotein, protein coding gene, tumor neoantigen, cytokine, enzyme, tumor antigen, surface protein and other type of molecules) and route of administration (intramuscular, intravenous, intranasal and other routes of administration).
- A detailed overview of the current market of players engaged in the development of mRNA vaccine and therapeutics, along with information on their year of establishment, company size (in terms of number of employees), location of headquarters, regional landscape and key players engaged in this domain.
- An in-depth company competitiveness analysis of players in mRNA vaccine and therapeutics domain, based on their developer strength (in terms of year of establishment and company size), pipeline strength (in terms of its pipeline maturity and drug administration route) and number of therapeutic areas targeted.
- Elaborate profiles of key companies engaged in mRNA vaccine and therapeutics market. Each profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and leadership team), financial information, mRNA vaccines and therapeutics pipeline, recent developments and an informed future outlook.
- A review of the various mRNA-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated in 2021), featuring a heat map representation that highlights mRNA therapeutics and vaccines under development (in partnership with core mRNA-focused entities), along with information on funding amount raised, partnership activity, and diversity of product portfolio (in terms of disease indication being treated and focus therapeutic area), as well as a spider web representation, comparing the initiatives of big pharmaceutical players on the basis of multiple relevant parameters.
- An analysis of start-ups (established since 2016) in this domain, based on several relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development. This chapter also provides details on amount raised, number of investors and number of deals inked.
- An analysis of completed, ongoing and planned clinical studies of mRNA therapeutics and vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, therapeutic area, study design, type of sponsor / collaborator, leading industry players (in terms of number of trials conducted), enrolled patient population and geography.
- An analysis of recent collaborations and partnerships within the mRNA therapeutics and vaccines industry, based on several relevant parameters, such as year of partnership, type of partnership, therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, since 2013.
- A detailed analysis of various investments made by players in this domain, since 2013, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital, IPOs, secondary offerings, debt, grants and other offerings), amount invested, therapeutic area, most active players (in terms of number of funding instances and amount invested) and key investors (in terms of number of funding instances).
- An in-depth analysis of the various patents that have been filed / granted related to mRNA therapeutics and vaccines domain, since 2016, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical region, CPC symbols, leading industry players (in terms of the number of patents filed / granted) and patent valuation.
- An in-depth analysis of the factors that can impact the growth of the market. It also features information on key drivers, potential restraints, emerging opportunities, and existing challenges within the mRNA vaccine and therapeutics market.
- A detailed mRNA vaccine and therapeutics market forecast analysis with our estimates of the existing market size, market value and future opportunity for mRNA vaccine and therapeutics companies over the next 11 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market size during the forecast period 2024-2035.
- Detailed projections of the current and future opportunity within the mRNA vaccine and therapeutics market across different application area, such as Covid-19 and other indications.
- Detailed projections of the current and future opportunity within the mRNA vaccines & therapeutics market across different target disease indication, such as influenza, respiratory syncytial virus infection and cytomegalovirus diseases.
- Detailed projections of the current and future opportunity within the mRNA vaccine and therapeutics market across different geographical regions, such as North America, Europe, Asia-Pacific, Latin America and Rest of the World.
- The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
- Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
- The report provides stakeholders with a pulse on the mRNA Vaccine and Therapeutics Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
- Arcturus Therapeutics
- BioNTech
- CureVac
- Ethris
- IMMORNA
- Moderna
- Providence Therapeutics
- RNACure
- Suzhou Abogen Biosciences
- Turn Biotechnologies
- Gennova
- Innovac Therapeutics
- Kernal Biologics
- Pantherna Therapeutics
- pHion Therapeutics
- Recode Therapeutics
- Rejuvenation Technologies
- RNAimmune
- Strand Therapeutics
- Walvax
- Ziphius Vaccines
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook